Clinical Edge Journal Scan

Prostate cancer: Surgery lowers mortality risk in high-risk group


 

Key clinical point: Radical prostatectomy vs external beam radiotherapy (EBRT) is associated with significant improvement in cancer-specific mortality in patients with National Comprehensive Cancer Network (NCCN) high-risk and Johns Hopkins University (JH) very high-risk prostate cancer.

Major finding: Cancer-specific mortality (CSM) was significantly lower with radical prostatectomy vs EBRT in NCCN high-risk combined group (2.3% vs 4.1%; hazard ratio [HR], 0.68; P < .001) and JH very high-risk subgroup (3.5% vs 6.0%; HR, 0.58; P < .001). There was no significant difference in CSM between 2 treatments in JH high-risk patient subgroup ( P = .2).

Study details: Study of 24,407 NCCN high-risk patients with prostate cancer identified from the Surveillance, Epidemiology, and End Results database between 2010 and 2016. Patients were subcategorized into JH high-risk and very high-risk groups.

Disclosures: No funding source was identified for this work. The authors declared no conflict of interests.

Source: Cheirigo F et al. J Urol. 2021 Sep 24. doi: 10.1097/JU.0000000000002250 .

Recommended Reading

Prostate cancer: SBRT safe in older patients with baseline anticoagulant use
Federal Practitioner
Clinical Edge Journal Scan Commentary: Prostate Cancer November 2021
Federal Practitioner
Urine test for prostate cancer signals amount of aggressive tumor
Federal Practitioner
Higher prostate cancer incidence in MSH2 and MSH6 carriers
Federal Practitioner
Prostate cancer: Salvage LDR brachytherapy after EBRT shows good response
Federal Practitioner
mCRPC: Enzalutamide effective in real-world setting
Federal Practitioner
Increase in PSA testing after 2017 USPSTF recommendations
Federal Practitioner
Prostate cancer screening: Racial disparities in MRI use after elevated PSA results
Federal Practitioner
Prostate cancer: Surgery shows survival advantage in high-risk African Americans
Federal Practitioner
Dietary changes may lower the risk for lethal prostate cancer
Federal Practitioner